Search Results
You are looking at 1 - 2 of 2 items for
- Author: Bin Du x
- Refine by access: All content x
Search for other papers by Yajie Guo in
Google Scholar
PubMed
Search for other papers by Junjie Yu in
Google Scholar
PubMed
Search for other papers by Chunxia Wang in
Google Scholar
PubMed
Search for other papers by Kai Li in
Google Scholar
PubMed
Search for other papers by Bin Liu in
Google Scholar
PubMed
Search for other papers by Ying Du in
Google Scholar
PubMed
Search for other papers by Fei Xiao in
Google Scholar
PubMed
Search for other papers by Shanghai Chen in
Google Scholar
PubMed
Search for other papers by Feifan Guo in
Google Scholar
PubMed
MicroRNAs, a class of small noncoding RNAs, are implicated in controlling a variety of biological processes. We have shown that leucine deprivation suppresses lipogenesis by inhibiting fatty acid synthase (FAS) expression in the liver previously; the aim of our current study is to investigate which kind of microRNA is involved in the regulation of FAS expression in response to leucine deprivation. Here, we indicated that microRNA-212-5p specifically binds to mouse FAS 3′UTR and inhibits its activity. Leucine deficiency significantly increased the mRNA levels of miR-212-5p in the livers of mice. Further studies proved that miR-212-5p also directly binds to the 3′UTR of stearoyl-CoA desaturase-1 (SCD1) to inhibit its activity. Overexpression of miR-212-5p decreases the protein levels of FAS and SCD1 in vitro and in vivo, and silencing of miR-212-5p has the opposite effects in mouse primary hepatocytes. Moreover, overexpression of miR-212-5p significantly decreases triglyceride (TG) accumulation in primary hepatocytes and in the livers of mice injected with adenovirus-mediated overexpressing of miR-212-5p (Ad-miR-212). Interestingly, inhibition of miR-212-5p reverses the suppressive effects of leucine deficiency on FAS and SCD1 expression, as well as TG accumulation in mouse primary hepatocytes. Finally, we demonstrate that leucine deficiency induces the expression of miR-212-5p in a GCN2/ATF4-dependent manner. Taken together, our results demonstrate a novel function of hepatic miR-212-5p in the regulation of lipid metabolism which represents a potential therapeutic target for the treatment of non-alcohol fatty liver diseases (NAFLD).
Search for other papers by Dong Li in
Google Scholar
PubMed
Search for other papers by Chenhao Cao in
Google Scholar
PubMed
Search for other papers by Zhuofan Li in
Google Scholar
PubMed
Search for other papers by Zhiyong Chang in
Google Scholar
PubMed
Search for other papers by Ping Cai in
Google Scholar
PubMed
Search for other papers by Chenxi Zhou in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
Search for other papers by Kaihua Li in
Google Scholar
PubMed
Search for other papers by Bin Du in
Google Scholar
PubMed
Icariside II, a flavonoid glycoside, is the main component found invivo after the administration of Herba epimedii and has shown some pharmacological effects, such as prevention of osteoporosis and enhancement of immunity. Increased levels of marrow adipose tissue are associated with osteoporosis. S100 calcium-binding protein A16 (S100A16) promotes the differentiation of bone marrow mesenchymal stem cells (BMSCs) into adipocytes. This study aimed to confirm the anti-lipidogenesis effect of Icariside II in the bone marrow by inhibiting S100A16 expression. We used ovariectomy (OVX) and BMSC models. The results showed that Icariside II reduced bone marrow fat content and inhibited BMSCs adipogenic differentiation and S100A16 expression, which correlated with lipogenesis. Overexpression of S100A16 eliminated the inhibitory effect of Icariside II on lipid formation. β-catenin participated in the regulation adipogenesis mediated by Icariside II/S100A16 in the bone. In conclusion, Icariside II protects against OVX-induced bone marrow adipogenesis by downregulating S100A16, in which β-catenin might also be involved.
